Indacaterol Maleate and Glycopyrronium Bromide Powder

Generic Name: Indacaterol Maleate and Glycopyrronium Bromide Powder

Indication: 用于慢性阻塞性肺病（慢阻肺，COPD）成人患者维持治疗，用于缓解慢阻肺（COPD）患者症状。

Clinical Trials

A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD

Phase 3

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: HL231 Solution for Inhalation
Drug: Ultibro 110μg/50 μg

First Posted Date: 2024-10-15

Last Posted Date: 2024-10-15

Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Target Recruit Count: 474

Registration Number: NCT06643078

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

ANTES B+ Clinical Trial

Phase 4

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Drug: Brimica
Drug: Duaklir
Drug: Ultibro
Drug: Ulunar
Drug: Xoterna
Drug: Anoro
Drug: Laventair
Drug: Spiolto Respimat
Drug: Yanimo
Drug: Foradil
Drug: Broncoral
Drug: Formoterol stada
Drug: Oxis
Drug: Formatris
Drug: Formoterol Aldo
Drug: Onbrez
Drug: Oslif
Drug: Hirobriz
Drug: Striverdi
Drug: Beglan
Drug: Betamican
Drug: Inaspir
Drug: Serevent
Drug: Soltel
Drug: Eklira
Drug: Bretaris
Drug: Seebri
Drug: Tovanor
Drug: Enurev
Drug: Spiriva
Drug: Tavulus
Drug: Sirkava
Drug: Braltus
Drug: Gregal
Drug: Incruse
Drug: Rolufta

First Posted Date: 2024-02-28

Last Posted Date: 2024-03-05

Lead Sponsor: Fundacio Privada Mon Clinic Barcelona

Target Recruit Count: 1028

Registration Number: NCT06282861

Locations: 🇪🇸
Hospital Clínic Barcelona, Barcelona, Catalunya, Spain

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Indacaterol maleate and glycopyrronium bromide
Drug: Ultibro Breezhaler with oral charcoal

First Posted Date: 2021-04-22

Last Posted Date: 2021-09-28

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 34

Registration Number: NCT04856098

Locations: 🇫🇮
CRST Helsinki Oy, Helsinki, Finland

Description of the Ability to Learn How to Handle Inhaler Devices in COPD

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Seretide® Diskus® 500/550 μg
Drug: Ultibro® Breezhaler® 110/50 μg
Drug: Spiriva® Respimat® 2,5 μg

First Posted Date: 2016-06-24

Last Posted Date: 2022-02-14

Lead Sponsor: University Hospital, Bordeaux

Target Recruit Count: 24

Registration Number: NCT02813200

Locations: 🇫🇷
CIC-P - Centre François Magendie - G3 - Hôpital Haut-Lévêque, Bordeaux, France

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: CHF 5993 + Ultibro matched placebo
Drug: Ultibro + CHF 5993 matched placebo
Procedure: Central spirometry
Other: COPD assessment test
Procedure: Local laboratory Assessments
Other: Saint George's Respiratory Questionnaire
Other: EXACT-pro questionnaire

First Posted Date: 2015-10-20

Last Posted Date: 2021-10-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 1532

Registration Number: NCT02579850

Locations: 🇮🇹
Chiesi Farmaceutici S.p.A., Parma, Italy

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

Phase 4

Completed

Conditions: COPD

Interventions: Drug: Spiriva®
Drug: Ultibro®

First Posted Date: 2015-10-02

Last Posted Date: 2019-06-07

Lead Sponsor: Laval University

Target Recruit Count: 50

Registration Number: NCT02567214

Locations: 🇨🇦
McGill University, Montreal, Quebec, Canada
🇨🇦
Queens University, Kingston, Ontario, Canada
🇨🇦
Laval University - IUCPQ, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy